Why Nigeria Still Struggles to Contain Lassa Fever
A virus Nigeria has known for more than half a century is again killing at a rate that should unsettle everyone.
The latest NCDC-linked figures — 936 confirmed Lassa fever cases and 224 deaths across 23 states — are not just another seasonal alert. They are a reminder that Nigeria is still losing people to a disease whose routes of transmission are well understood, whose risk factors are familiar, and whose worst outcomes can often be reduced with faster diagnosis, safer care, and earlier treatment.
Lassa fever is not new. It was first identified in 1969 in the town of Lassa in present-day Borno State. It is now endemic in parts of West Africa, with Nigeria reporting recurring outbreaks, especially during the dry season. The frustrating part is not that the virus exists. It is that the country keeps meeting it with systems that are too slow, too unequal, and too underfunded to stop preventable deaths.
A familiar virus with an unforgiving timeline
Lassa fever is caused by Lassa virus, an arenavirus carried mainly by the multimammate rat, Mastomys natalensis. People are usually infected through food, household items, or surfaces contaminated by rodent urine or droppings. In crowded homes where grain is stored in open containers, waste disposal is poor, and rats move freely between kitchens and sleeping areas, prevention is not simply a matter of “public awareness.” It is a matter of housing, sanitation, food storage, and poverty.
The disease is also hard to spot early. Many patients begin with fever, weakness, headache, sore throat, cough, nausea, vomiting, or abdominal pain — symptoms that overlap with malaria, typhoid, COVID-19, and other common infections. In a typical clinic, especially in rural Nigeria, a feverish patient may be treated first for malaria. If the person does not improve, the next step may come days later. By then, the virus may have advanced, and the window for the best treatment response may be narrowing.
This is one reason the death toll remains high. Ribavirin, an antiviral used in Lassa fever management, is considered most useful when given early. But “early” requires suspicion, testing, transport, and referral systems that work quickly. For many patients, that chain breaks before it starts.
Why outbreaks keep turning deadly
Nigeria has improved Lassa fever surveillance over the years. The Nigeria Centre for Disease Control and Prevention publishes situation reports, coordinates emergency operations during outbreaks, and supports laboratory diagnosis. But surveillance is not the same as universal access to care.
A person in a village in Ondo, Edo, Bauchi, Ebonyi, Taraba, or Benue may live hours away from a facility that can collect samples properly, isolate suspected cases, manage complications, and protect health workers. Even when samples can be collected, transport delays matter. So do electricity, personal protective equipment, oxygen, dialysis capacity, blood products, and trained staff.
Severe Lassa fever can cause bleeding, shock, seizures, kidney injury, and multi-organ failure. Some survivors suffer hearing loss. Pregnant women, especially in late pregnancy, face extremely high risks, and fetal loss is common. That means a Lassa outbreak is not just a tally of confirmed infections; it is an X-ray of the country’s emergency-care capacity.
Health-care transmission remains another dangerous weak point. Lassa fever can spread from person to person through contact with infected blood, urine, feces, vomit, or other body fluids, particularly in clinical settings where infection prevention is weak. A single missed case in a crowded ward can expose nurses, doctors, cleaners, relatives, and other patients. In Nigeria, health workers have repeatedly been among the victims of Lassa outbreaks — a sign that the system often asks front-line staff to take risks without giving them reliable protection.
The prevention message is right — but incomplete
The standard advice is sensible: store food in rodent-proof containers, keep homes clean, dispose of waste properly, block holes that allow rats into houses, avoid drying food on roadsides, and do not eat rats. But public-health messaging can sound hollow when it ignores the conditions in which people live.
How does a family “keep rats out” when walls are cracked, doors do not seal, refuse collection is irregular, and food must be bought in bulk because markets are far away? How does a community reduce rodent exposure when drainage is poor and waste piles up for weeks? How does a household isolate a sick relative when six people share one room?
The science is clear, but the intervention has to be social as well as medical. Rodent control requires local government sanitation, better waste management, safer grain storage, and community-level environmental action. Risk communication must be delivered in local languages through trusted channels — not only during headline outbreaks, but before the dry-season surge begins.
Schools, religious groups, market associations, women’s cooperatives, and agricultural networks can all play roles. A farmer storing maize, a trader drying garri, a pregnant woman with fever, and a nurse triaging patients at night each needs different information and different tools.
The missing pieces: speed, trust, and research
The practical goal is not mysterious: detect cases earlier, treat patients faster, prevent hospital spread, and reduce rodent contact. But achieving that requires investment long before an outbreak peaks.
First, primary health centres need stronger fever-triage systems. In endemic states, clinicians should be trained to suspect Lassa fever when malaria treatment fails or when symptoms suggest severe viral haemorrhagic fever. Rapid referral protocols should be simple and rehearsed.
Second, diagnostic networks must get closer to patients. Nigeria has expanded molecular testing capacity, but distance still costs lives. Faster sample transport, better cold-chain logistics, and more supported laboratories in high-burden zones would shorten the time between suspicion and treatment.
Third, infection prevention cannot be optional. Gloves, gowns, masks, hand hygiene, sharps safety, isolation space, and waste handling are basic outbreak infrastructure. They protect health workers and keep hospitals from becoming amplifiers.
Fourth, Nigeria and its partners must keep pushing vaccine and therapeutic research. There is still no widely available licensed Lassa fever vaccine. Several candidates have been studied, and global health organizations have identified Lassa fever as a priority disease because of its epidemic potential. But endemic countries need to be more than trial sites; they should be central partners in research design, surveillance, manufacturing strategy, and deployment planning.
Finally, trust matters. People delay care when they fear costs, stigma, poor treatment, or being isolated far from family. Outbreak control improves when communities believe the health system is there to help them, not blame them.
Lassa fever is deadly, but it is not an unknowable threat. Nigeria knows the reservoir. It knows the seasonality. It knows the high-risk states. It knows the clinical danger signs and the infection-control failures that turn hospitals into transmission points.
The question is whether that knowledge can be converted into routine protection: cleaner environments, faster diagnosis, safer clinics, earlier treatment, and sustained research. Until then, each new headline will feel painfully familiar — another outbreak that was predictable, another death toll that was not inevitable.